Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2022-12-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于哈药集团股份有限公司2022年第二次临时股东大会之法律意见书
Regulatory Filings
2022-12-23 Chinese
哈药集团有限公司关于哈药股份股票交易异常波动问询函的回复
Regulatory Filings
2022-12-13 Chinese
哈药集团股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by 哈药集团股份有限公司. It details the unusual price movements of the company's stock over three consecutive trading days, confirms that no undisclosed material information exists, and warns investors about market risks. The document is short (1367 characters) and serves as a regulatory disclosure about stock price volatility rather than a financial report or management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is a typical regulatory announcement about stock price abnormality, fitting the category of Regulatory Filings (RNS).
2022-12-13 Chinese
哈药集团股份有限公司2022年第二次临时股东大会会议材料
AGM Information Classification · 95% confidence The document is titled as materials for the "2022 Second Extraordinary General Meeting" of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It includes detailed meeting agenda, voting procedures, and proposed resolutions such as increasing bank credit limits and amendments to the company's articles of association and meeting rules. The content is focused on the preparation and materials for a shareholders' meeting, including procedural rules and proposals to be voted on. There is no indication that this is a report of the meeting results or a financial report. The document is clearly a set of meeting materials provided to shareholders before or during the meeting. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or Extraordinary General Meeting. The document length is substantial and contains detailed agenda and proposals, consistent with meeting materials rather than a brief announcement or voting results.
2022-12-12 Chinese
哈药集团股份有限公司监事会议事规则（2022年12月）
Governance Information Classification · 100% confidence The document is titled as the "Supervisory Board Rules" of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the governance structure, duties, rights, meeting procedures, and responsibilities of the supervisory board members. It references relevant laws and regulations such as the Company Law, Securities Law, and listing rules. The content is focused on internal governance rules and procedures rather than financial data, earnings, or announcements. There is no indication that this is a report of financial results, an audit, or a regulatory filing. It is a governance document outlining the supervisory board's rules and practices, which fits the definition of Governance Information (CGR). The document length is sufficient and contains detailed governance content, not just an announcement or summary, so it is not RPA or RNS.
2022-12-06 Chinese
哈药集团股份有限公司九届三十二次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It includes multiple board decisions such as approval of a 2023-2027 action plan, internal management restructuring, signing of a compensation agreement, and revisions to various governance documents. It also announces the scheduling of a shareholders' meeting. The document is not a full annual or interim report, nor is it a financial statement or earnings release. It is not a proxy solicitation or voting results announcement, but rather a formal disclosure of board decisions and governance-related changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related governance decisions. The document length is 2811 characters, which is consistent with a detailed board resolution announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2022-12-06 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.